CN104284679B - 药物制剂 - Google Patents

药物制剂 Download PDF

Info

Publication number
CN104284679B
CN104284679B CN201380013848.1A CN201380013848A CN104284679B CN 104284679 B CN104284679 B CN 104284679B CN 201380013848 A CN201380013848 A CN 201380013848A CN 104284679 B CN104284679 B CN 104284679B
Authority
CN
China
Prior art keywords
formula
compound
lactose
magnesium stearate
metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380013848.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104284679A (zh
Inventor
R.L.M.布勒克斯
W.F.M.菲利尔斯
P.H.J.尼斯特
A.H.科普曼斯
F.M.C.范侯特
C.利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respivert Ltd
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49160309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104284679(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of CN104284679A publication Critical patent/CN104284679A/zh
Application granted granted Critical
Publication of CN104284679B publication Critical patent/CN104284679B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380013848.1A 2012-03-13 2013-03-13 药物制剂 Expired - Fee Related CN104284679B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261610012P 2012-03-13 2012-03-13
US201261610023P 2012-03-13 2012-03-13
US61/610012 2012-03-13
US61/610,012 2012-03-13
US61/610023 2012-03-13
US61/610,023 2012-03-13
PCT/GB2013/050623 WO2013136075A1 (en) 2012-03-13 2013-03-13 Novel pharmaceutical formulations

Publications (2)

Publication Number Publication Date
CN104284679A CN104284679A (zh) 2015-01-14
CN104284679B true CN104284679B (zh) 2017-08-04

Family

ID=49160309

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380013848.1A Expired - Fee Related CN104284679B (zh) 2012-03-13 2013-03-13 药物制剂
CN201380013851.3A Expired - Fee Related CN104302650B (zh) 2012-03-13 2013-03-13 晶体pi3激酶抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380013851.3A Expired - Fee Related CN104302650B (zh) 2012-03-13 2013-03-13 晶体pi3激酶抑制剂

Country Status (35)

Country Link
US (3) US20150099768A1 (enExample)
EP (2) EP2834244B1 (enExample)
JP (3) JP6189874B2 (enExample)
KR (2) KR20140141596A (enExample)
CN (2) CN104284679B (enExample)
AU (2) AU2013234080B2 (enExample)
CA (2) CA2864652A1 (enExample)
CL (2) CL2014002386A1 (enExample)
CO (2) CO7051030A2 (enExample)
CR (2) CR20140417A (enExample)
CY (1) CY1118565T1 (enExample)
DK (1) DK2834244T3 (enExample)
EA (2) EA025465B1 (enExample)
EC (2) ECSP14018142A (enExample)
ES (2) ES2650791T3 (enExample)
GT (2) GT201400182A (enExample)
HR (1) HRP20161383T1 (enExample)
HU (1) HUE029420T2 (enExample)
IL (2) IL233886A (enExample)
IN (2) IN2014MN01998A (enExample)
LT (1) LT2834244T (enExample)
MX (2) MX355299B (enExample)
MY (1) MY171125A (enExample)
NI (2) NI201400100A (enExample)
NZ (2) NZ627963A (enExample)
PE (2) PE20142342A1 (enExample)
PH (2) PH12014501713A1 (enExample)
PL (1) PL2834244T3 (enExample)
PT (1) PT2834244T (enExample)
SG (2) SG11201404522VA (enExample)
SI (1) SI2834244T1 (enExample)
TW (2) TWI586378B (enExample)
UA (1) UA115544C2 (enExample)
WO (2) WO2013136076A1 (enExample)
ZA (2) ZA201407373B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
NZ627963A (en) 2012-03-13 2015-08-28 Respivert Ltd Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HK1214159A1 (zh) 2012-11-08 2016-07-22 Rhizen Pharmaceuticals S.A. 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
TR201818680T4 (tr) * 2014-07-09 2019-01-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi İnhalasyona yönelik formülasyonların hazırlanması için bir proses.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
MY204600A (en) 2016-04-15 2024-09-05 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239932A1 (en) * 2003-07-11 2006-10-26 Monteith Michael J Pharmaceutical formulations comprising magnesium stearate
WO2011048111A1 (en) * 2009-10-19 2011-04-28 Respivert Limited Compounds

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2003006628A2 (en) 2001-07-13 2003-01-23 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
JP2007524605A (ja) 2003-04-03 2007-08-30 ピーディーエル バイオファーマ，インコーポレイティド インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
LT2612862T (lt) * 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
EP1750714A1 (en) 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
JP2008501707A (ja) 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20080287469A1 (en) 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
EP2032605A2 (en) 2006-05-24 2009-03-11 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
CA2655720A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
EP2155753A1 (en) * 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
EP2365810A2 (en) 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
EP2379505A4 (en) 2008-12-05 2012-10-17 Designmedix Inc MODIFIED CHLOROQUINE WITH SINGLE RING UNIT OR CONDENSED RING UNIT
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
RU2012104214A (ru) 2009-08-05 2013-09-10 Верситек Лимитед Противовирусные соединения и способы их получения и применения
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (zh) * 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) * 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
US20130157991A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
WO2012041717A1 (en) 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) * 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
NZ627963A (en) 2012-03-13 2015-08-28 Respivert Ltd Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239932A1 (en) * 2003-07-11 2006-10-26 Monteith Michael J Pharmaceutical formulations comprising magnesium stearate
WO2011048111A1 (en) * 2009-10-19 2011-04-28 Respivert Limited Compounds

Also Published As

Publication number Publication date
US20170239256A1 (en) 2017-08-24
SG11201404522VA (en) 2014-10-30
UA115544C2 (uk) 2017-11-27
SG11201404519UA (en) 2014-10-30
EA201491675A1 (ru) 2014-12-30
TW201350139A (zh) 2013-12-16
CN104302650B (zh) 2017-07-18
PT2834244T (pt) 2016-11-03
TWI586378B (zh) 2017-06-11
AU2013234080A1 (en) 2014-08-21
ES2600705T3 (es) 2017-02-10
PH12014501922A1 (en) 2014-11-24
PE20142342A1 (es) 2015-01-16
PE20141964A1 (es) 2014-12-01
ECSP14018630A (es) 2015-09-30
LT2834244T (lt) 2016-11-10
US20150105408A1 (en) 2015-04-16
CR20140416A (es) 2014-10-31
JP2018008992A (ja) 2018-01-18
TW201400484A (zh) 2014-01-01
NI201400101A (es) 2016-11-30
HRP20161383T1 (hr) 2016-12-02
IL233883A0 (en) 2014-09-30
EA025465B1 (ru) 2016-12-30
US9642799B2 (en) 2017-05-09
US20150099768A1 (en) 2015-04-09
NI201400100A (es) 2015-01-12
MX2014010991A (es) 2014-10-13
MX2014010990A (es) 2014-10-13
MX357170B (es) 2018-06-27
KR20140131971A (ko) 2014-11-14
CL2014002385A1 (es) 2015-01-09
HK1203487A1 (zh) 2015-10-30
PH12014501713A1 (en) 2014-10-13
EP2825202A1 (en) 2015-01-21
ES2650791T3 (es) 2018-01-22
CR20140417A (es) 2014-10-31
CL2014002386A1 (es) 2015-02-27
CO7051030A2 (es) 2014-09-10
CN104284679A (zh) 2015-01-14
WO2013136076A1 (en) 2013-09-19
IL233886A (en) 2017-12-31
ZA201407373B (en) 2016-10-26
TWI617561B (zh) 2018-03-11
DK2834244T3 (en) 2016-11-28
JP2015509973A (ja) 2015-04-02
KR20140141596A (ko) 2014-12-10
CN104302650A (zh) 2015-01-21
CA2864643A1 (en) 2013-09-19
IN2014MN01998A (enExample) 2015-08-14
SI2834244T1 (sl) 2016-12-30
EA201491674A1 (ru) 2014-12-30
EP2834244A1 (en) 2015-02-11
NZ628072A (en) 2015-08-28
JP6189874B2 (ja) 2017-08-30
JP2015509972A (ja) 2015-04-02
EP2834244B1 (en) 2016-08-10
HK1203812A1 (en) 2015-11-06
CY1118565T1 (el) 2017-07-12
WO2013136075A1 (en) 2013-09-19
GT201400182A (es) 2015-09-17
NZ627963A (en) 2015-08-28
IN2014MN02000A (enExample) 2015-08-14
ZA201407374B (en) 2016-10-26
GT201400183A (es) 2015-07-08
HUE029420T2 (en) 2017-02-28
MY171125A (en) 2019-09-26
AU2013234081B2 (en) 2017-02-02
EP2825202B1 (en) 2017-09-06
CA2864652A1 (en) 2013-09-19
AU2013234080B2 (en) 2016-12-22
ECSP14018142A (es) 2015-06-30
EA023715B1 (ru) 2016-07-29
MX355299B (es) 2018-04-11
AU2013234081A1 (en) 2014-08-21
PL2834244T3 (pl) 2017-01-31
CO7061079A2 (es) 2014-09-19

Similar Documents

Publication Publication Date Title
CN104302650B (zh) 晶体pi3激酶抑制剂
CN105229007B (zh) 2‑((4‑氨基‑3‑(3‑氟‑5‑羟基苯基)‑1h‑吡唑并[3,4‑d]嘧啶‑1‑基)甲基)‑3‑(2‑(三氟甲基)苄基)喹唑啉‑4(3h)‑酮衍生物和其作为磷酸肌醇3‑激酶抑制剂的用途
ZA200401002B (en) Inhalation compositions comprising tricyclic 5,6-dihydro-9H-pyrazolo (3,4-C)-1.2.4-triazolo (4,3-alpha) pyridines.
HK1203812B (en) Stabilization of pharmaceutical compositions
HK1203487B (en) Crystalline pi3 kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170804

Termination date: 20190313

CF01 Termination of patent right due to non-payment of annual fee